A Real-World Study Comparing Effectiveness of Deucravacitinib and Apremilast in Japanese Adults With Plaque Psoriasis

What this Trial Is About

Researchers are conducting a real-world, prospective observational study in Japan to compare the effectiveness of two treatments, deucravacitinib and apremilast, for adults diagnosed with plaque psoriasis. This study focuses on participants who have begun treatment under normal medical care, aiming to gather data on how these therapies perform outside controlled clinical trial settings. Participants in this study are adults with plaque psoriasis who have recently started treatment with either deucravacitinib or apremilast as prescribed by their doctors. The study observes these participants over time without assigning treatments, tracking outcomes according to routine care. Data is collected at multiple follow-up points 1 month, 3 months, 6 months, and every 6 months up to 5 years. During the study, researchers will measure changes in the percentage of body surface area affected by psoriasis, improvements in physician assessments, severity indexes, and quality of life scores. Treatment duration and various clinical scores will be recorded regularly to understand long-term effects. Participants will be followed for up to five years, with data collected through regular visits and assessments to monitor treatment outcomes and disease progress.

A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)